Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex for bladder dysfunction in multiple sclerosis
2016-000840-32Phase 4Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cannabidiol in multiple sclerosis (MS), sponsored by Carlo Besta Neurological Institute. Primary endpoint: Improvement in urodynamic parameters between pre- and post-treatment evaluations. Started Jun 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-000840-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000840-32.